acorafloxacin

Acorafloxacin (also known as avarofloxacin and by the code names JNJ-Q2 and JNJ-32729463) is a broad-spectrum fluoroquinolone antibacterial agent. It was originally developed by Janssen and later licensed to Furiex Pharmaceuticals (a subsidiary of Forest Laboratories). Acorafloxacin exhibits potent in vitro and in vivo activity against a wide range of Gram-positive and Gram-negative bacteria, including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and ciprofloxacin-resistant MRSA. Its primary indications were for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The drug acts by inhibiting bacterial DNA synthesis through direct inhibition of DNA gyrase (responsible for negative helical supercoiling) and DNA topoisomerase IV (responsible for separating nucleotide strands), both essential enzymes for bacterial replication. Acorafloxacin demonstrated a higher barrier to resistance compared to other fluoroquinolones. Despite promising Phase 2 results showing efficacy comparable to linezolid or moxifloxacin with good tolerability, development was discontinued after Phase 2/3 trials[4][5][7].

Other names

acorafloxacin hydrochlorideavarofloxacinUNII-1NWW5SKQ0NUNII1NWW5SKQ0NUNII 1NWW5SKQ0N